Revance Therapeutics, Inc. - RVNC STOCK NEWS

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the publication of two peer-reviewed articles in the Aesthetic Surgery Journal, focusing on injection techniques for treating glabellar lines. The studies emphasize the importance of precise interactions to optimize aesthetic results, highlighting the influence of injection techniques on eyebrow positioning. The first article evaluates how subtle differences in injection affect outcomes, while the second presents a systematic assessment algorithm for personalized treatments. This reflects Revance's ongoing commitment to enhancing patient care and outcomes in aesthetic treatments.

Revance Therapeutics, Inc. (Nasdaq: RVNC) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A conference call and live webcast are scheduled for 4:30 p.m. ET the same day to discuss the results and provide updates on business and pipeline initiatives. Revance specializes in innovative aesthetic and therapeutic offerings, including the DAXXIFY™ injection and biosimilar development for BOTOX®. The call will be accessible via registration, with a replay available for 30 days post-call.

Revance Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the FDA for DAXXIFY™ to treat cervical dystonia, a painful condition affecting neck muscles. The application is based on the ASPEN Phase 3 clinical program, showcasing DAXXIFY’s median response duration of 24 weeks. The company anticipates a PDUFA target action date in 2023. Successful approval could position Revance in the nearly $1 billion U.S. muscle movement disorder market, significantly reducing treatment frequency for patients.

Revance Therapeutics (RVNC) appointed Dr. David A. Hollander as Chief Medical Officer to enhance clinical development and regulatory strategies. This leadership change comes as the company prepares for the commercial launch of Daxxify™, recently approved by the FDA for glabellar lines, and the advancement of its biosimilar to Botox®. Dr. Hollander brings over 20 years of experience, having previously held prominent roles in R&D and regulatory affairs at Aerie Pharmaceuticals and Allergan. His extensive background is expected to bolster Revance's growth in aesthetics and therapeutics.

Revance Therapeutics (RVNC) presented two video abstracts on DAXXIFY™ at the ASDS Annual Meeting, showcasing its efficacy and safety across diverse patient subgroups. Highlights of the presentations include strong patient satisfaction and successful elimination of glabellar lines in black patients, reaffirming DAXXIFY™ as a pioneering treatment in aesthetic medicine. DAXXIFY™ is a FDA-approved long-lasting neuromodulator, promising year-long results with limited treatments. Revance continues to emphasize their commitment to innovation in facial aesthetics.

Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29 in Nantucket, MA. CEO Mark Foley is scheduled to present on September 28 at 9:00 A.M. EST. A live audio webcast will be accessible from the Investor Relations section of the company's website and a replay will be available for 30 days post-event. Revance focuses on innovative aesthetic and therapeutic solutions, including products like DAXXIFY™ and a biosimilar to BOTOX®.

Revance Therapeutics (NASDAQ: RVNC) announced the publication of two peer-reviewed articles in Aesthetic Surgery Journal regarding the effects of DAXXIFY™ on glabellar lines. The studies showed DAXXIFY™ significantly improved eyebrow position with a response duration of over 24 weeks across various age and race subgroups. In a post-hoc analysis, patients experienced a positive reduction in frontalis muscle activity. The safety profile was consistent across demographics, with common adverse events including headache and injection site reactions.

Revance Therapeutics presented positive results from its Phase 2 JUNIPER clinical trial for DAXXIFY™, targeting upper limb spasticity in adults post-stroke or brain injury. The 500U dose showed a median response duration of 24 weeks and was well tolerated. The drug's effectiveness may potentially reduce treatment frequency by 50% annually. Results will be shared at the MDS Congress on September 16, enhancing the company's prospects in a market valued at $756 million, projected to exceed $1 billion by 2025.

Revance Therapeutics announced the closing of its public offering of 9.2 million shares at $25.00 per share, raising gross proceeds of $230 million. The offering saw the complete exercise of the underwriters' option for 1.2 million additional shares. The shares were offered under an automatic shelf registration statement previously filed with the SEC on November 27, 2020. Goldman Sachs, Cowen, Guggenheim, and Barclays acted as joint book-running managers for this offering, with full details available on the SEC's website.